Answers are grounded in this paper and cite their sources.
BG12 (Tecfidera) is an oral medication composed of dimethyl fumarate (DMF) that has been approved for the treatment of relapsing-remitting multiple sclerosis (MS). DMF has anti-inflammatory but also putative neuroprotective mechanisms of action. Neuroprotection is hypothesized to be mediated by activation of the nuclear factor (erythroid-derived 2)-related factor 2 (Nrf2) antioxidant pathway. Nrf2 nuclear translocation was shown in neurons, oligodendrocytes, and astrocytes in experimental autoimmune encephalomyelitis, an animal model of MS, as well as in astrocytes in vitro after DMF application.1,2 This nuclear translocation of the transcription …
No takes yet. Share an insight, caveat, or question.
Metz et al. (2015) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: